IBL HealthCare Limited
By PSX Investors Zone · Updated October 24, 2026
IBL HealthCare Limited (PSX: IBLHL) is a Pakistani healthcare-products distribution and marketing company incorporated in 1997 and listed on the Pakistan Stock Exchange. Its principal activities include marketing, selling and distributing healthcare and pharmaceutical products across categories including nutrition, sweeteners and beverages, and medical and surgical disposables. The company is a subsidiary of The Searle Company Limited. In FY2026, IBL HealthCare reported revenue of Rs4.607 billion, profit after tax of Rs220.402 million and EPS of Rs2.24, compared with revenue of Rs4.322 billion and profit after tax of Rs208.371 million in FY2025. The board declared no cash dividend for FY2026. IBLHL was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial data. Investors should also note that PSX currently displays a Risk Warning Alert concerning potential trading suspension or delisting, making the latest exchange notices essential reading.
IBL HealthCare Limited (PSX: IBLHL) is a Pakistan Stock Exchange-listed company engaged in the marketing, selling and distribution of healthcare and pharmaceutical products. Incorporated on July 14, 1997, the company was converted into a public limited company in November 2008.
Its business covers multiple healthcare-related product categories, including nutrition, sweeteners and beverages, and medical and surgical disposables. IBL HealthCare is a subsidiary of The Searle Company Limited, while International Brands (Private) Limited is identified in its annual report as the ultimate parent company.
Important PSX Risk Warning
The official PSX company page currently displays the following Risk Warning Alert:
The Company is in continuous violation as specified in Clauses 5.11.1. or 5.11.2. and carry risk of suspension of trading or being delisted from the Exchange and may be subject to such terms and conditions as specified by the Exchange.
This warning is material and should remain prominent in the company profile. The wording identifies a risk of suspension of trading or delisting; it does not, on its own, confirm that either action has already occurred.
Investors should review the latest PSX announcements to establish the nature of the violation, any corrective measures taken by the company, applicable deadlines and whether the exchange has subsequently updated or withdrawn the warning.
Official reference: PSX — IBL HealthCare Limited.
Business Overview
IBL HealthCare operates primarily as a marketer, seller and distributor of healthcare and pharmaceutical products. Its reported product categories include:
- Nutrition: Products serving infant and adult nutrition markets.
- Sweeteners and beverages: Products in the sweetener and beverage category.
- Medical and surgical disposables: Healthcare consumables and related products used in medical settings.
According to its FY2026 annual report, medical and surgical disposables generated the largest share of reported revenue among these product lines. Nutrition also represented a significant business category.
As a distribution-focused company, IBL HealthCare's performance depends on product availability, supplier relationships, demand from healthcare customers, pricing, distribution efficiency, inventory control and the ability to collect receivables. Its results should be evaluated in light of these operating factors rather than assuming that distribution revenue behaves like pharmaceutical-manufacturing revenue.
Official references: IBL HealthCare investor information and FY2026 annual report.
Financial Performance
For the year ended June 30, 2026, IBL HealthCare reported growth in revenue, gross profit and profit after tax.
| Financial Metric | FY2026 | FY2025 |
|---|---|---|
| Revenue | Rs4,607.109 million | Rs4,322.471 million |
| Gross profit | Rs1,644.842 million | Rs1,446.970 million |
| Profit before tax | Rs401.256 million | Rs377.093 million |
| Profit after tax | Rs220.402 million | Rs208.371 million |
| EPS | Rs2.24 | Rs2.11* |
| Gross profit margin | 35.70% | 33.48% |
| Net profit margin | 4.78% | 4.82% |
FY2025 EPS was restated following the bonus-share issue.
Revenue increased by approximately 6.6%, while gross profit increased by approximately 13.7%. Profit after tax rose by approximately 5.8%. The improvement in gross margin suggests better gross profitability relative to revenue, although the net profit margin remained broadly stable.
Marketing and distribution expenses increased during FY2026, reflecting higher operating and promotional expenditure. Finance costs declined, while the annual report also identifies a tax expense that included a charge related to super tax.
Investors should assess the complete audited financial statements to understand how gross profit converts into net earnings and cash flow, particularly as marketing expenditure, tax and receivables can affect the final result.
Official sources: PSX financials and FY2026 annual report.
Latest Quarterly Results
For the quarter ended March 31, 2026, the PSX financial table reported the following figures:
| Financial Metric | Q3 FY2026 | Q3 FY2025 |
|---|---|---|
| Sales | Rs1,212.720 million | Rs948.027 million |
| Profit after tax | Rs61.889 million | Rs35.444 million |
| EPS | Rs0.63 | Rs0.36 |
Quarterly sales increased by approximately 27.9%, while profit after tax increased by approximately 74.6% compared with the corresponding quarter. These are quarterly results, not full-year figures.
Investors should compare these results with subsequent quarters and the annual report to understand the persistence of growth, changes in product mix, marketing expenditure and operating cash flow.
Official reference: PSX company profile and financials.
Dividend and Bonus Shares
The board decided not to declare a cash dividend for the year ended June 30, 2026, citing the need to preserve cash and support future investment and growth plans.
The annual report also records a bonus-share issue of 15 shares for every 100 shares held during the preceding reporting period. This bonus issue is distinct from a cash dividend and should not be described as a FY2026 cash payout.
Investors should check the official PSX payout and corporate-action records for the relevant approval dates and entitlement details.
Official references: PSX payouts and announcements and IBL HealthCare investor information.
Shariah Compliance Status
IBL HealthCare Limited was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published on May 29, 2026. That screening was based on financial data as of December 31, 2025.
The published ratios were:
- Debt ratio: 0.49%
- Non-compliant investment ratio: 0.00%
- Non-compliant income ratio: 0.00%
- Illiquid assets ratio: 44.17%
These figures apply to the stated screening date and methodology. They should not be presented as newly calculated ratios based on the June 2026 annual accounts.
Investors seeking Shariah-compliant investments should verify the latest official PSX-KMI All Share Islamic Index screening and any subsequent Shariah-related announcements before making investment decisions.
Official source: PSX-KMI All Share Islamic Index recomposition, May 2026.
Key Factors Investors Should Monitor
- Revenue growth: Monitor demand across nutrition, sweeteners and beverages, and medical and surgical disposables.
- Gross margins: Track pricing, product mix and procurement costs.
- Distribution expenses: Assess whether marketing and selling costs are translating into sustainable sales growth.
- Working capital: Review inventory, receivables, supplier payments and operating cash flow.
- Finance costs: Monitor borrowings and the cost of financing.
- Dividend policy: The company declared no cash dividend for FY2026.
- Exchange compliance: Review the current PSX Risk Warning Alert and subsequent official notices.
- Shariah screening: Confirm the latest official classification rather than relying indefinitely on the May 2026 screening.
Frequently Asked Questions
What is IBL HealthCare Limited's PSX symbol?
Its Pakistan Stock Exchange symbol is IBLHL.
What does IBL HealthCare Limited do?
The company markets, sells and distributes healthcare and pharmaceutical products across nutrition, sweeteners and beverages, and medical and surgical disposables.
Was IBL HealthCare profitable in FY2026?
Yes. It reported profit after tax of Rs220.402 million and EPS of Rs2.24 for the year ended June 30, 2026.
Did IBL HealthCare declare a cash dividend for FY2026?
No. The board declared no cash dividend for FY2026.
Is IBL HealthCare Shariah-compliant?
It was classified as compliant in the PSX-KMI All Share Islamic Index recomposition published May 29, 2026, based on December 2025 financial data. Investors should check the latest official screening before relying on this status.
What does the PSX Risk Warning Alert mean?
The alert warns that continuing violations under specified PSX clauses may lead to trading suspension or delisting. The latest exchange announcements should be checked to establish the precise circumstances and current status.
Has IBL HealthCare already been delisted?
The warning alone does not establish that the company has been delisted. Check the latest official PSX status and notices before drawing that conclusion.
Official Sources
- Pakistan Stock Exchange — IBL HealthCare Limited
- IBL HealthCare — Official Website
- IBL HealthCare — Investor Information
- FY2026 Annual Report
- PSX-KMI All Share Islamic Index Recomposition — May 2026
The financial information above relates to the stated reporting periods. Before publication, recheck the latest exchange warning, any subsequent regulatory notices, corporate entitlements and current Shariah screening.
This profile is for educational purposes and is not a recommendation to buy or sell any security.